Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
about
Diabetes DyslipidemiaTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsEfficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysisCanagliflozin Treatment in Patients with Type 2 Diabetes MellitusSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionCanagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 DiabetesUpdate on the treatment of type 2 diabetes mellitusSGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysisImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinRisk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trialsComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsEfficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesQuality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusLong-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesA clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Patient profiling in diabetes and role of canagliflozin.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsEfficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination.Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis
P2860
Q26750905-8BB221A7-395A-4449-BECF-5AB531183D1AQ26751258-6FD87497-F9C0-45E0-BBFD-3D3089414391Q26773558-EBDE9ED0-7D52-46C7-B290-9BE11A6ECD1DQ26777529-20F7D0C6-DE21-4F0B-9CA0-5DD13302A865Q26864336-9A37D630-9C41-4EC3-9641-91A4EFE3CB66Q27021870-92152CA3-4185-4DEE-9289-98CDAB467DCFQ27027105-894975B8-FD4B-406F-83AA-969BEAE845F7Q28072339-63AF92EA-9E5B-4DAA-AB62-5814A8F2B61EQ28073342-E7A595B9-3E03-412A-B325-BEAEB22A284BQ28076978-8B015B24-DD0D-407D-818B-9EAA15C7FDC6Q28080114-C8957C19-9388-4595-87D0-F261190CFD7FQ28250844-A083DA12-DFBD-4841-90AF-18F8EA1DDC7EQ28544980-4018F1BF-FB7C-41DF-B06B-78E01758AD90Q28546797-B6CC48C2-E816-42FC-860B-E0F99C1CEBD1Q28553482-795CE4FB-C773-4408-97D1-5A813060A629Q30240823-F5C60440-0480-49FC-B275-06317506EDB5Q30241808-D07F76E2-0B3C-4A66-A630-7BEAE1974B2AQ30248634-4F31A6D8-CF8B-4FF8-9C92-A5CB47FBFBC2Q30846870-3D447AB7-C80B-4712-8C1D-676906994B24Q32186373-11DF81C7-5494-4506-B31F-2DA3395A3118Q33567077-5600A6E9-82AD-4F95-9BE0-0DF2F2609C41Q33613143-0BB5B72A-E2E0-4BD7-AC3E-AB23BD2A1A32Q33781497-669DCB09-4EC6-4E00-9764-E4BDA8183734Q33802278-08D17274-39B7-400B-81EE-EB1AE461AAA9Q33871321-C19915F1-17BB-451B-A992-196F4D9149E8Q33885732-219E5DD0-BB19-4314-81A7-915B22244A23Q34105064-B128AE67-AE3B-43E7-AF2B-E4AE73CC7EE4Q34161881-BC2F09C0-0789-43C0-AAB1-18BD9B5A9E90Q34198692-BD42E5C7-5513-4A98-96F5-E50CEFE01F0BQ34264365-0CB613C2-3852-4D4D-9B5D-F3F339F8C272Q34543009-E4FD4B33-FB72-4CE3-9F3C-00260F0ED691Q34563587-DFDA4510-83CB-4C6D-88A2-444BC139AE2FQ34726437-6A01E3CF-758A-4272-AF43-93A7D5F0A0DCQ34729268-8BF79B93-8F10-4CDF-B90B-5B299442DFA6Q34973750-ADBDD185-0D0B-4BAA-8333-6DDA1B623B57Q35192198-6B42D468-CE3D-4036-B39F-E0656546F6A3Q35225256-C623CA57-2EBD-4659-8CD9-4AEB598D612EQ35236019-40AFDBC9-23D4-4530-B546-96A23EE6CEFCQ35799131-A2DC8035-AFB2-4ACB-A972-A161D5D69494Q35830021-AB0EDE2B-6FBA-4506-9596-749757E442C8
P2860
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of canagli ...... onotherapy: a randomised trial
@en
Efficacy and safety of canagli ...... notherapy: a randomised trial.
@nl
type
label
Efficacy and safety of canagli ...... onotherapy: a randomised trial
@en
Efficacy and safety of canagli ...... notherapy: a randomised trial.
@nl
prefLabel
Efficacy and safety of canagli ...... onotherapy: a randomised trial
@en
Efficacy and safety of canagli ...... notherapy: a randomised trial.
@nl
P2093
P2860
P921
P1433
P1476
Efficacy and safety of canagli ...... onotherapy: a randomised trial
@en
P2093
P2860
P2888
P304
P356
10.1007/S00125-013-3039-1
P577
2013-09-13T00:00:00Z